Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JAVADIN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of chronic hepatitis C virus (HCV) infection in combination with other antiviral agents,Investigational use for emerging viral infections such as COVID-19
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
400 mg orally once daily
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is 8.2 hours (range 6.5–10.1) in patients with normal renal function; prolonged to 18–24 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by CYP3A4 and CYP2C9 isoenzymes in the liver. Minor contribution from glucuronidation via UGT1A1. Active metabolite M1 is formed and further cleared renally.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Renal elimination of unchanged drug accounts for 85% of clearance; biliary/fecal elimination accounts for 10%; 5% metabolized.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
92% bound to albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
1.2 L/kg (range 0.9–1.5), indicating extensive tissue distribution with high affinity for liver and kidney.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral: 75% (range 60–85%) due to first-pass metabolism; intramuscular: 95%.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
e GFR 30-89 m L/min: no adjustment; e GFR 15-29 m L/min: 200 mg once daily; e GFR <15 m L/min: not recommended
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Weight ≥40 kg: 400 mg once daily; Weight 20-39 kg: 200 mg once daily; Weight <20 kg: not established
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment; monitor renal function due to age-related decline
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: HEPATOTOXICITY. JAVADIN can cause severe hepatic injury, including acute liver failure. Monitor liver function tests (LFTs) before and during treatment. Discontinue if signs of hepatic decompensation occur.
None.
Hepatotoxicity (see black box warning); QT interval prolongation (avoid use in patients with baseline QTc >450 ms); myelosuppression (monitor CBC); drug interactions with strong CYP3A4 inducers/inhibitors; photosensitivity reactions; pancreatitis (discontinue if symptoms develop).
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Absolute: History of hypersensitivity to JAVADIN or any component; severe hepatic impairment (Child-Pugh class C); concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine). Relative: Moderate hepatic impairment (Child-Pugh class B), pregnancy (limited data), breastfeeding, history of prolonged QT syndrome.
Hypersensitivity to AURLUMYN or any of its components.
Take with meals to minimize GI side effects. Avoid grapefruit juice as it may alter drug metabolism. No other significant food restrictions.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: risk of fetal hypotension, renal impairment, and oligohydramnios due to decreased placental perfusion. Avoid use unless benefit outweighs risk.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in nursing infants including hypotension and renal impairment. Breastfeeding is not recommended during therapy and for at least 24 hours after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
Increased plasma volume and renal clearance in pregnancy may require dose escalation; however, higher doses increase fetal risk. No established dose adjustments available. Use lowest effective dose with careful monitoring. Empirical dose increase by 25-50% if therapeutic response inadequate, but weigh against fetal risks.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
JAVADIN (hydroxychloroquine sulfate) requires baseline and periodic ophthalmologic exams due to risk of irreversible retinal toxicity, especially after cumulative dose >200g or use >5 years. Caution in patients with G6PD deficiency, psoriasis, and porphyria. Avoid concurrent use with QT-prolonging agents. Monitor renal and hepatic function.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Take with food or milk to reduce gastrointestinal upset.,Report any vision changes immediately, such as blurred vision, reading difficulties, or light sensitivity.,Do not exceed prescribed dose; overdose can be fatal.,Avoid alcohol as it may increase liver toxicity risk.,Use sunscreen and protective clothing to reduce photosensitivity.,Inform all healthcare providers you are taking JAVADIN.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JAVADIN vs AURLUMYN, answered by our medical review team.
JAVADIN is a Antineoplastic Agent that works by JAVADIN is a synthetic flavonoid derivative that acts as a potent inhibitor of viral RNA-dependent RNA polymerase (Rd Rp), thereby blocking viral replication. It also modulates the host immune response by upregulating interferon signaling and reducing pro-inflammatory cytokine production.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JAVADIN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JAVADIN is: 400 mg orally once daily. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JAVADIN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JAVADIN is classified as Category C. FDA Pregnancy Category C. First trimester: potential for neural tube defects and cardiac malformations based on animal studies; limited human data. Second and third trimesters: ris. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.